The U.S. government has awarded Moderna $590 million to advance the development of its bird flu vaccine, as the country ...
The current public-health risk is low, but the CDC is watching the situation carefully and working with states to monitor ...
Moderna receives $590M contract from HHS for mRNA-based bird flu vaccine; up 4% in after-hours trading. Read more here.
Moderna secured a $590 million package from the U.S. Health and Human Services Department to accelerate the development of its bird influenza vaccine as concerns about a bird flu pandemic in humans ...
Given the uncertainty regarding its top-line growth, we would advise short-term investors to steer clear of MRNA stock.
Moderna will see a reduction in its R&D expenses as a result, but will retain full control of the programmes. The deal was announced alongside a vaccine R&D update from Moderna, which now has 28 ...
Separately, the UK government purchased 60 million doses of Moderna’s COVID-19 vaccine, which may include an updated booster vaccine candidate against the newer variants like Omicron if ...
Moderna stock has fallen over the past four years, but shares got a boost on positive comments about AI. Is MRNA stock a buy ...
In 2023, Moderna initiated a study on a “pandemic influenza vaccine” to protect against H5 and H7 avian influenza viruses. In July, the company received $176 million from HHS toward its ...